Kyle what’s our market share ?

[anonymous]

Please share my friend!

 

[anonymous]

OMG. How is Kyle still around? He is the most useless, least accomplished marketer in the history of pharma.

 

[anonymous]

OMG. How is Kyle still around? He is the most useless, least accomplished marketer in the history of pharma.

because he does not use idiotic acronyms like OMG

 

[anonymous]

Market share is outlined below.

 

[anonymous]

OMG. How is Kyle still around? He is the most useless, least accomplished marketer in the history of pharma.

Think about it this way. How do KF, MH and RG keep their jobs with such ineptitude and poor performance.
It can ONLY be because they’ve got keys to the closet of skeletons. There’s no other possible explanation.

 

[anonymous]

Think about it this way. How do KF, MH and RG keep their jobs with such ineptitude and poor performance.
It can ONLY be because they’ve got keys to the closet of skeletons. There’s no other possible explanation.

#Abhaypics

 

[anonymous]

#Abhaypics

And moving up the chain, he then has #dilippics

 

[anonymous]

Market share is outlined below.

Everything about this company is ‘zero point zero’ hahaha

 

[anonymous]

Kyle is leaving SUN.

 

[anonymous]

Kyle is leaving SUN.

Word up, son

 

[anonymous]

What does this mean?

 

[anonymous]

Kyle is leaving SUN.

Medicare eligible, finally.
Sold his soul to Mumbai to get this far.

 

[anonymous]

Medicare eligible, finally.
Sold his soul to Mumbai to get this far.

He must have finally gotten enough of a package to sign an agreement that he’ll never release and info incl pics about AG and DS.

 

[anonymous]

He must have finally gotten enough of a package to sign an agreement that he’ll never release and info incl pics about AG and DS.

Yup, that’d be my bet too!

 

[anonymous]

Kyle owned the Ilumya failure. He couldn’t get the FRMs to perform their job. 85% turnover in fully qualified, successful TMs. There was <20% pull through of covered, payable covered drug enrollments submitted. Largely due to no pull through from FRMs, the constant training of new TMs and no support from Managed Markets. He had CEO and CFO ears but was afraid to give any bad news. So now everyone pays the price for his ineptitude.

 

[anonymous]

Kyle owned the Ilumya failure. He couldn’t get the FRMs to perform their job. 85% turnover in fully qualified, successful TMs. There was <20% pull through of covered, payable covered drug enrollments submitted. Largely due to no pull through from FRMs, the constant training of new TMs and no support from Managed Markets. He had CEO and CFO ears but was afraid to give any bad news. So now everyone pays the price for his ineptitude.

Clueless you are

 

[anonymous]

Kyle owned the Ilumya failure. He couldn’t get the FRMs to perform their job. 85% turnover in fully qualified, successful TMs. There was <20% pull through of covered, payable covered drug enrollments submitted. Largely due to no pull through from FRMs, the constant training of new TMs and no support from Managed Markets. He had CEO and CFO ears but was afraid to give any bad news. So now everyone pays the price for his ineptitude.

All that sounds about right, but you have to say, in any legit pharma company, he, and many others, would have been fired many years ago.
It really points towards there being something, something that he - and a couple of others - have on AG and DS.
I’m talking very serious stuff, like things that could compromise their freedom. That’s just my opinion.

 

[anonymous]

He must have finally gotten enough of a package to sign an agreement that he’ll never release and info incl pics about AG and DS.

BINGO !
Nailed it. He finally got the right exit package at sun. I’m sure he had to sign away all his rights to possess any documents or PHOTOS

 

[anonymous]

Kyle left for a CEO position at another company

 

[anonymous]

Kyle owned the Ilumya failure. He couldn’t get the FRMs to perform their job. 85% turnover in fully qualified, successful TMs. There was <20% pull through of covered, payable covered drug enrollments submitted. Largely due to no pull through from FRMs, the constant training of new TMs and no support from Managed Markets.

Market Access group was barely aware of who he was, and didn’t answer to him in any capacity. The low pull through percentage was because TMs are desperate for any business and tell offices to send in everything. Most of which was MedAdv payers, resulting is PAP cases going through the roof assuming the office didn’t just give up on the process mid-journey.